Skip to the content
FSHD Europe

FSHD Europe

FSHD

  • Home
  • About Us
    • Member Organisations
    • Contact
    • Who we are…
      • Sheila Hawkins
      • Paola de Donato
  • News
    • Events
    • Stories
  • What is FSHD
  • FSHD European Trial Network
    • What is it about?
    • Core Group of Experts
  • Research
    • Guidelines
    • Clinical trials
  • Governance
    • Policies
    • Financial Reports
    • Statutes
  • Links
Clinical trials News Recent research

Fulcrum announces results from ReDUX4 Trial with Losmapimod in FSHD

June 24, 2021 By Bine Haase
Fulcrum-Therapeutics-Announces-Results-from-ReDUX4-Trial-with-Losmapimod-in-Facioscapulohumeral-Muscular-Dystrophy-FSHD-Demonstrating-Slowed-Disease-Progression-and-Improved-FunctionDownload

Post navigation

Previous PostPrevious Today is World FSHD Day!
Next PostNext A “patient friendly” summary by FSHD Society on the results of Fulcrums phase 2b study on Losmapimod
Proudly powered by WordPress | Theme: Popularis